The Influence of miR-3149 on the Malignancy Progression of Gastric Cancer by Negatively Regulating CEACAM5

Authors

  • Ruiwen Zhao Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • Deyao Zhao Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • Xiaorong Zhu Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • Fengying Li Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • Pingping Xiong College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, 471003, China
  • Siting Li Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • Junqi Liu Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

DOI:

https://doi.org/10.62382/jcbt.v1i1.1

Keywords:

Gastric Cancer, miR-3149, CEACAM5, Malignancy Progression

Abstract

Background: There are some reports indicating that carcinoembryonic antigen associated cell adhesion molecule 5 (CEACAM5) can act as a diagnostic indicator or molecular marker for GC, but its upstream regulatory pathway still needs to be explored. microRNAs (miRNAs) regulate gene expression at the translation level and fulfil a crucial role in GC physiologyin, whether miR-3149 in family members can affect GC progression by regulating CEACAM5 is still unclear.

Methods: miR-3149 and CEACAM5 expressions in GC tissues and cells (N87, AGS, and HGC-27) were observed by RT-qPCR or Western blot. Intervened the miR-3149 and CEACAM5 expression in GC cells, CCK8, Wound healing, Transwell and flow cytometry assays evaluated cell activity and function separately, while detecting related proteins. Predicted the target of miR-3149 and the expression of CEACAM5 in tumor tissue through bioinformatics analysis and evaluated the correlation between both using Spearman analysis. Verified the targeting relationship between the two through the Luciferase reporter assay. Conducted another rescue experiment on CEACAM5 overexpression to further verify this relationship.

Results: In GC tissues and cells, miR-3149 and CEACAM5 expression levels were respectively down-regulated and up-regulated. Transfection of miR-3149 mimics or inhibitors respectively reduced or increased GC cell apoptosis and inhibited or encouraged cell proliferation, migration and invasion, which were shown to be enhanced or inhibited respectively by transfection of OE-CEACAM5/Si-CEACAM5, while their apoptosis rate decreased or increased. miR-3149 could target regulating CEACAM5, and showed an inverse correlation with the expression of CEACAM5. The impacts of miR-3149 mimics on the malignancy progression of GC could be partially reversed by OE-CEACAM5.

Conclusion: The results indicate that miR-3149 can downregulate the expression of CEACAM5 to inhibit the malignancy progression, as a GC suppressor,which identify a new miRNA mediated tumor suppressor mechanism in GC.

Downloads

Download data is not yet available.

References

Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin. Med. J. (Engl.) 134, 783-791 (2021). https://doi.org/10.1097/CM9.0000000000001474

Lee YH, Chan WH, Lai YC, Chen AH, Chen CM. Gastric hydrodistension CT versus CT without gastric distension in preoperative TN staging of gastric carcinoma: analysis of single-center cancer registry. Sci. Rep. 12, 11321 (2022). https://doi.org/10.1038/s41598-022-15619-3

Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 401, 1655-1668 (2023). https://doi.org/10.1016/S0140-6736(23)00620-7

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 396, 635-648 (2020). https://doi.org/10.1016/S0140-6736(20)31288-5

Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J. Hematol. Oncol. 16, 57 (2023). https://doi.org/10.1186/s13045-023-01451-3

Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet. 38, 613-626 (2022). https://doi.org/10.1016/j.tig.2022.02.006

Budakoti M, Panwar AS, Molpa D, Singh RK, Büsselberg D, Mishra AP, Coutinho HDM, Nigam M. Micro-RNA: The darkhorse of cancer. Cell. Signal. 83, 109995 (2021). https://doi.org/10.1016/j.cellsig.2021.109995

Solé C, Lawrie CH. MicroRNAs in Metastasis and the Tumour Microenvironment. Int. J. Mol. Sci. 22, 4859 (2021). https://doi.org/10.3390/ijms22094859

Grasso G, Higuchi T, Mac V, Barbier J, Helsmoortel M, Lorenzi C, Sanchez G, Bello M, Ritchie W, Sakamoto S, Kiernan R. NF90 modulates processing of a subset of human pri-miRNAs. Nucleic Acids Res. 48, 6874-6888 (2020). https://doi.org/10.1093/nar/gkaa386

Pan G, Liu Y, Shang L, Zhou F, Yang S. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer communications (London, England). 41, 199-217 (2021). https://doi.org/10.1002/cac2.12138

Liu H, Xiang Y, Zong QB, Zhang XY, Wang ZW, Fang SQ, Zhang TC, Liao XH. miR-6745-TIMP1 axis inhibits cell growth and metastasis in gastric cancer. Aging (Albany N. Y.) 13, 24402-24416 (2021). https://doi.org/10.18632/aging.203688

Pan Y, Shu X, Sun L, Yu L, Sun L, Yang Z, Ran Y. miR-196a-5p modulates gastric cancer stem cell characteristics by targeting Smad4. Int. J. Oncol. 50, 1965-1976 (2017). https://doi.org/10.3892/ijo.2017.3965

Jiao T, Huang Y, Sun H, Yang L. Exosomal lnc-CDHR derived from human umbilical cord mesenchymal stem cells attenuates peritoneal epithelial-mesenchymal transition through AKT/FOXO pathway. Aging. 15, 6921-6932 (2023). https://doi.org/10.18632/aging.204883

Zhang X, Tan J, Chen Y, Ma S, Bai W, Peng Y, Shi G. Identification of serum MiRNAs as candidate biomarkers for non-small cell lung cancer diagnosis. BMC Pulm Med. 22, 479 (2022). https://doi.org/10.1186/s12890-022-02267-6

Bai M, Che Y, Lu K, Fu L. Analysis of deubiquitinase OTUD5 as a biomarker and therapeutic target for cervical cancer by bioinformatic analysis. PeerJ. 8, e9146 (2020). https://doi.org/10.7717/peerj.9146

Decary S, Berne PF, Nicolazzi C, Lefebvre AM, Dabdoubi T, Cameron B, Rival P, Devaud C, Prades C, Bouchard H, Cassé A, Henry C, Amara C, Brillac C, Ferrari P, Maçon L, Lacoste E, Combeau C, Beys E, Naimi S, Blanc V. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors. Clin Cancer Res. 26, 6589-6599 (2020). https://doi.org/10.1158/1078-0432.CCR-19-4051

Wang X, Li Y, Pan M, Lu T, Wang M, Wang Z, Liu C, Hu G. CEACAM5 inhibits the lymphatic metastasis of head and neck squamous cell carcinoma by regulating epithelial-mesenchymal transition via inhibiting MDM2. Clin Sci (Lond). 136, 1691-1710 (2022). https://doi.org/10.1042/CS20220581

Zhang X, Han X, Zuo P, Zhang X, Xu H. CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration. J Int Med Res. 48, 300060520959478 (2020). https://doi.org/10.1177/0300060520959478

Toh J, Hoppe MM, Thakur T, Yang H, Tan KT, Pang B, Ho S, Roy R, Ho KY, Yeoh KG, Tan P, Sundar R, Jeyasekharan A. Profiling of gastric cancer cell-surface markers to achieve tumour-normal discrimination. BMJ Open Gastroenterol. 7, e000452 (2020). https://doi.org/10.1136/bmjgast-2020-000452

Zhang L, Zhang C, Liu N. CEACAM5 targeted by miR-498 promotes cell proliferation, migration and epithelial to mesenchymal transition in gastric cancer. Transl Oncol. 24, 101491 (2022). https://doi.org/10.1016/j.tranon.2022.101491

Cao J, Yang Y, Duan B, Zhang H, Xu Q, Han J, Lu B. LncRNA PCED1B-AS1 mediates miR-3681-3p/MAP2K7 axis to promote metastasis, invasion and EMT in gastric cancer. Biology direct. 19, 34 (2024). https://doi.org/10.1186/s13062-024-00468-z

Yu Y, Baral S, Sun Q, Ding J, Zhang Q, Zhao F, Gao S, Yao Q, Yu H, Liu B, Wang D. PLCD3 inhibits apoptosis and promotes proliferation, invasion and migration in gastric cancer. Discover oncology. 15, 26 (2024). https://doi.org/10.1007/s12672-024-00881-w

Huang P, Xia L, Guo Q, Huang C, Wang Z, Huang Y, Qin S, Leng W, Li D. Genome-wide association studies identify miRNA-194 as a prognostic biomarker for gastrointestinal cancer by targeting ATP6V1F, PPP1R14B, BTF3L4 and SLC7A5. Front Oncol. 12, 1025594 (2022). https://doi.org/10.3389/fonc.2022.1025594

Wang J, Zhang M, Hu X, She J, Sun R, Qin S, Li D. miRNA-194 predicts favorable prognosis in gastric cancer and inhibits gastric cancer cell growth by targeting CCND1. FEBS open bio. 11, 1814-1826 (2021). https://doi.org/10.1002/2211-5463.13125

Cheng L, Li X, Dong W, Yang J, Li P, Qiang X, Yin J, Guo L. LAMC2 regulates the proliferation, invasion, and metastasis of gastric cancer via PI3K/Akt signaling pathway. J Cancer Res Clin Oncol. 150, 230 (2024). https://doi.org/10.1007/s00432-024-05720-7

Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 40, e108647 (2021). https://doi.org/10.15252/embj.2021108647

Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 15, 129 (2022). https://doi.org/10.1186/s13045-022-01347-8

Zheng X, Dai F, Feng L, Zou H, Feng L, Xu M. Communication Between Epithelial-Mesenchymal Plasticity and Cancer Stem Cells: New Insights Into Cancer Progression. Front Oncol. 11, 617597 (2021). https://doi.org/10.3389/fonc.2021.617597

Bai HX, Qiu XM, Xu CH, Guo JQ. MiRNA-145-5p inhibits gastric cancer progression via the serpin family E member 1-extracellular signal-regulated kinase-1/2 axis. World J Gastrointest Oncol. 16, 2123-2140 (2024). https://doi.org/10.4251/wjgo.v16.i5.2123

Liu Y, Lin W, Zhao F, Liu Y, Sun J, Hu J, Li J, Chen J, Zhang X, Vai MI, Shum PP, Shao L. A Multimode Microfiber Specklegram Biosensor for Measurement of CEACAM5 through AI Diagnosis. Biosensors. 14, 57(2024). https://doi.org/10.3390/bios14010057

Ling T, Zhang C, Liu Y, Jiang C, Gu L. Single-cell analysis revealed a potential role of T-cell exhaustion in colorectal cancer with liver metastasis. J Cell Mol Med. 28, e18341 (2024). https://doi.org/10.1111/jcmm.18341

Matsumura Y, Ito Y, Mezawa Y, Sulidan K, Daigo Y, Hiraga T, Mogushi K, Wali N, Suzuki H, Itoh T, Miyagi Y, Yokose T, Shimizu S, Takano A, [32]Terao Y, Saeki H, Ozawa M, Abe M, Takeda S, Okumura K, Orimo A. Stromal fibroblasts induce metastatic tumor cell clusters via epithelial-mesenchymal plasticity. Life Sci Alliance. 2, e201900425(2019). https://doi.org/10.26508/lsa.201900425

Downloads

Published

2024-07-09

How to Cite

Zhao, R., Zhao, D., Zhu, X., Li, F., Xiong, P., Li, S., & Liu, J. (2024). The Influence of miR-3149 on the Malignancy Progression of Gastric Cancer by Negatively Regulating CEACAM5. Journal of Cancer Biomoleculars and Therapeutics, 1(1), 1–10. https://doi.org/10.62382/jcbt.v1i1.1

Issue

Vol. 1 No. 1 (2024)

Section

Articles

License

Copyright (c) 2024 Journal of Cancer Biomoleculars and Therapeutics

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.